Published in ScientificWorldJournal on March 20, 2013
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol (2014) 1.04
Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci (2014) 1.00
Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne) (2014) 0.88
Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol (2016) 0.81
Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease. J Nutr Biochem (2015) 0.81
Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome (2014) 0.80
Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. J Diabetes Res (2015) 0.79
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol (2015) 0.78
Ameliorative potential of Tamarindus indica on high fat diet induced nonalcoholic fatty liver disease in rats. ScientificWorldJournal (2014) 0.78
Gastrointestinal morbidity in obesity. Ann N Y Acad Sci (2014) 0.77
Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med (2014) 0.77
In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM. World J Gastroenterol (2015) 0.76
Psoralea corylifolia L. Seed Extract Attenuates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice. Nutrients (2016) 0.76
Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol (2016) 0.75
The Wide and Complex Field of NAFLD Biomarker Research: Trends. ISRN Hepatol (2014) 0.75
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Thiazolidinediones. N Engl J Med (2004) 9.42
Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr (2004) 8.64
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology (2010) 8.05
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Long-term weight loss maintenance. Am J Clin Nutr (2005) 7.42
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem (2004) 5.80
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology (2011) 5.10
Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med (2000) 4.92
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia (2009) 3.33
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut (2008) 3.01
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol (2005) 2.46
Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol (2012) 2.39
From fat to inflammation. Gastroenterology (2006) 2.35
Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol (2008) 2.28
Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem (2009) 2.13
Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology (2011) 2.09
Ethnicity and nonalcoholic fatty liver disease. Hepatology (2012) 1.98
Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med (2006) 1.90
Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev (2008) 1.82
Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology (2010) 1.75
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2008) 1.74
Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol (2007) 1.72
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2008) 1.68
Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol (2009) 1.64
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther (2006) 1.58
Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation (2000) 1.57
Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol (2006) 1.56
Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care (2007) 1.45
Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol (2007) 1.43
Pharmacotherapies for obesity: past, current, and future therapies. J Obes (2010) 1.43
Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology (1990) 1.40
Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol (2008) 1.33
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol (2009) 1.21
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2011) 1.21
Lifestyle modification as the primary treatment of NASH. Clin Liver Dis (2009) 1.18
Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol (2011) 1.17
Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis (2012) 1.17
Origin of triacylglycerol moiety of plasma very low density lipoproteins in the rat: structural studies. J Lipid Res (1995) 1.13
Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis (2011) 1.08
Dietary polyunsaturated fats regulate rat liver sterol regulatory element binding proteins-1 and -2 in three distinct stages and by different mechanisms. J Nutr (2002) 1.08
Evaluation and management of non-alcoholic steatohepatitis. J Hepatol (2004) 1.07
Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med (2010) 1.05
A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology (1997) 1.05
Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis (2011) 1.01
Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2006) 1.01
ASH and NASH. Dig Dis (2011) 1.00
Espresso coffees, caffeine and chlorogenic acid intake: potential health implications. Food Funct (2011) 0.97
Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep (2010) 0.96
High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. Eur J Gastroenterol Hepatol (2007) 0.93
A randomized controlled trial for obesity and binge eating disorder: low-energy-density dietary counseling and cognitive-behavioral therapy. Behav Res Ther (2011) 0.92
Omega-3 fatty acids and liver disease. Hepatology (2007) 0.91
Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes (2007) 0.89
Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther (2005) 0.87
Less Smad2 is good for you! A scientific update on coffee's liver benefits. Hepatology (2009) 0.86
Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci (2008) 0.83
The influence of physical activity and inactivity on insulin action and secretion in man. Acta Physiol Scand Suppl (1992) 0.76
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev (2002) 1.49
Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl (2003) 1.19
Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology (2004) 1.10
Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl (2004) 1.05
Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients. Sex Transm Dis (2007) 1.04
The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol (2002) 0.96
Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol (2013) 0.91
Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. J Med Virol (2002) 0.91
Reactivation of sarcoidosis during interferon therapy. J Gastroenterol (2002) 0.90
Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant (2003) 0.88
Liver transplantation for alcoholic liver disease. Alcohol Res Health (2003) 0.87
Hepatic apoptosis and proliferation in male and female rats fed alcohol: role of cytokines. Alcohol Clin Exp Res (2003) 0.87
Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol (2008) 0.87
Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology (2002) 0.85
Hepatic estrogen receptors and alcohol intake. Mol Cell Endocrinol (2002) 0.85
Biomarkers of Oxidative Stress Study IV: ozone exposure of rats and its effect on antioxidants in plasma and bronchoalveolar lavage fluid. Free Radic Biol Med (2011) 0.84
Frequency of peritoneal infections among patients undergoing continuous paracentesis with an indwelling catheter. J Ayub Med Coll Abbottabad (2011) 0.81
Post-transplant IVC occlusion and thrombosis treated with tPA, heparin, and sharp recanalization. J Gastroenterol (2005) 0.81
Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin. Dig Dis Sci (2011) 0.80
A comparison of risk factors for HCV-mono-infection, HIV-mono-infection, and HCV/HIV-co-infection in a community setting. Dig Dis Sci (2007) 0.80
Effects of soybean extract on morphology and survival of Caco-2, SW620, and HT-29 cells. Nutr Cancer (2002) 0.79
Hepatitis C virus-associated pericardial effusion and tamponade in a liver transplant recipient. Can J Cardiol (2004) 0.79
Luminescence experiments involved in the mechanism of streptozotocin diabetes and cataract formation. Luminescence (2008) 0.79
Cardiovascular problems in cirrhotic patients. Turk J Gastroenterol (2004) 0.79
Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci (2003) 0.79
Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepatogastroenterology (2003) 0.78
Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy. Dig Dis Sci (2009) 0.78
Daily interferon therapy for chronic hepatitis C: a report of a community practice experience. Hepatogastroenterology (2002) 0.78
Markedly elevated alpha-fetoprotein levels without hepatocellular carcinoma. Hepatogastroenterology (2004) 0.78
Ultrasensitive peroxynitrite-based luminescence with L-012 as a screening system for antioxidative/antinitrating substances, e.g. Tylenol (acetaminophen), 4-OH tempol, quercetin and carboxy-PTIO. Luminescence (2007) 0.78
Hemostatic modulation with the liver dialysis device in humans with advanced liver disease. Hepatogastroenterology (2002) 0.77
Transjugular liver biopsy: comparison of sample adequacy with the use of two automated needle systems. J Vasc Interv Radiol (2010) 0.77
Celiac disease in patients with HCV genotype 1A. Am J Gastroenterol (2003) 0.77
Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study. Cytokine (2004) 0.77
Amelioration of hypertrophic cardiomyopathy using nonsurgical septal ablation in a cirrhotic patient prior to liver transplantation. Liver Transpl (2005) 0.77
Calponin is expressed by Sertoli cells within rat testes and is associated with actin-enriched cytoskeleton. Cell Tissue Res (2004) 0.76
Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepatogastroenterology (2003) 0.76
HELLP syndrome complicated bile duct injury and subsequent left hepatic lobe atrophy. Dig Dis Sci (2006) 0.76
Transverse myelitis occurring in association with primary biliary cirrhosis and Sjogren's syndrome. Dig Dis Sci (2003) 0.75
Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clin Transplant (1993) 0.75
Colonic diffuse large B-cell lymphoma in a liver transplant patient with historically very low tacrolimus levels. Case Rep Transplant (2012) 0.75
Nonocclusive mesenteric ischemia: reality. J Gastroenterol (2002) 0.75
Postoperative infections in cirrhotic patients. Hepatogastroenterology (2005) 0.75
Complete esophagogastric anastomotic disruption. Gastrointest Endosc (2003) 0.75
Ascites and kidney transplantation: case report and critical appraisal of the literature. Dig Dis Sci (2007) 0.75
Daily interferon monotherapy for chronic hepatitis C in patients with normal or near-normal serum alanine transaminase levels: a comparison of two protocols. South Med J (2005) 0.75
Retroperitoneal varices presenting as an adrenal pseudotumor in a cirrhotic patient. WMJ (2006) 0.75
An assessment of the accuracy of hepatic and splenic size based upon a clinician's physical examination, a radiologist's impression and the actual liver and spleen volumes calculated by CT scanning. Dig Dis Sci (2008) 0.75
Hepatic iron quantitation and its relationship with disease measures and histologically assessed iron content. Dig Dis Sci (2007) 0.75
First report of telaprevir-induced pancreatitis. Dig Dis Sci (2013) 0.75
Adenocarcinoma of the ileocecal valve occurring 35 years after jejunoileal bypass. South Med J (2008) 0.75
Pericardiocentesis and pancreatic aspiration needle biopsy in coagulopathic and thrombocytopenic cirrhotic patient. Chest (2003) 0.75
Splenic embolization in a Jehovah's Witness: role of recombinant human factor VIIa. Hepatogastroenterology (2003) 0.75